Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pramlintide and Fiasp Artificial Pancreas for T1D
NCT04163874Completed
- Sponsor
- McGill University
- Start
- Feb 2020
- Primary completion
- Jan 2022
- Modality
- Peptides
- Countries
- 1
01
Overview
Randomised, double-blind trial of pramlintide in type 1 diabetes mellitus (T1D) (3 arms), sponsored by McGill University. Primary endpoints: Time in Target Range at 12 days and Diabetes Distress Scale (Emotional Burden) at 12 days. Started Feb 2020; status: completed.
02
Drugs
pramlintide
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT04163874.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04163874.